Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily supplement shorten your cold? new study in seniors aims to find out

NCT ID NCT07431840

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a dietary supplement called IDP (Immune Defense Protein) can reduce the length and severity of cold and flu symptoms in people aged 60 and older. About 300 participants will take either a low or high dose of IDP or a placebo daily during cold and flu season. They will report their symptoms at home using a smartphone app, so no clinic visits are needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IDP (Immune Defense Protein) dietary supplement
What this could lead to
If it works, this could provide a simple, over-the-counter supplement to help older adults have milder and shorter colds or flu.
What could go wrong
This is an early-stage, consumer-driven study with self-reported data, so results may be less reliable. Supplements often show limited benefit in rigorous trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 60 years and older 2. Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season. 3. Able to read and understand English. 4. Able to read, understand, and provide informed consent. 5. Able to use a personal smartphone device and download Chloe by People Science. 6. Able to receive shipment of the product at an address within the United States. Exclusion Criteria: Any potential participants who: 1. Do not have a personal smartphone, internet access, or unwilling to download Chloe. 2. Already in an immunocompromised state, including: A. Infectious Causes * HIV/AIDS * Chronic hepatitis B or C (advanced stages) * Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related * Leukemia (e.g., AML, ALL, CLL) * Lymphoma (e.g., Hodgkin's and Non-Hodgkin's) * Multiple Myeloma * Any metastatic cancer receiving chemotherapy C. Immunosuppressive Therapy: Participants on: * Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks) * Biologics (e.g., TNF inhibitors like infliximab, adalimumab) * Calcineurin inhibitors (e.g., tacrolimus, cyclosporine) * mTOR inhibitors (e.g., sirolimus) * JAK inhibitors (e.g., tofacitinib) * Chemotherapy or radiation therapy * Anti-rejection meds post-organ transplant D. Transplant Patients * Solid organ transplant (kidney, liver, heart, lung) * Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants) * Rheumatoid Arthritis * Systemic Lupus Erythematosus (SLE) * Psoriasis or Psoriatic Arthritis * Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis) * Multiple Sclerosis (especially on disease-modifying therapies) 3. Other Concomitant Conditions and Therapies: 1. Any investigational therapies or treatments within 30 days prior to enrollment. 2. Known diagnosis of Asthma and/or COPD 3. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder 4. Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes 5. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes 4. Use of cannabis-containing products daily 5. Use of nicotine-containing products daily 6. Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids. 7. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • People Science, Inc.

    RECRUITING

    Los Angeles, California, 90045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.